NASDAQ:ADAG

Adagene - ADAG Stock Forecast, Price & News

$1.50

-0.02 (-1.32%)

(As of 03/24/2023 08:50 PM ET)

Add

Compare

Today's Range: $1.50
▼
$1.55
50-Day Range: $1.35
▼
$1.95
52-Week Range: $0.90
▼
$4.46

Volume: 1,700 shs
Average Volume: 25,289 shs
Market Capitalization: $64.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Institutional Ownership

Adagene MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 233.3% Upside
$5.00 Price Target
Short Interest: Healthy
0.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.47
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.72) to ($2.07) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

329th out of 1,005 stocks

Pharmaceutical Preparations Industry

147th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Adagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Adagene has a forecasted upside of 233.3% from its current price of $1.50.
Amount of Analyst Coverage
Adagene has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.02% of the float of Adagene has been sold short.
Short Interest Ratio / Days to Cover
Adagene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Adagene has recently decreased by 10.87%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Adagene does not currently pay a dividend.
Dividend Growth
Adagene does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ADAG.

2.5

News and Social Media Coverage

News Sentiment
Adagene has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Adagene this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for ADAG on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adagene insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.68% of the stock of Adagene is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Adagene are expected to decrease in the coming year, from ($1.72) to ($2.07) per share.
Price to Book Value per Share Ratio
Adagene has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Adagene (NASDAQ:ADAG) Stock

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

ADAG Stock News Headlines

March 21, 2023 | americanbankingnews.com

Adagene (NASDAQ:ADAG) Receives Buy Rating from HC Wainwright

March 21, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Adagene (ADAG)

March 27, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

March 16, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Hookipa Pharma (HOOK)

March 16, 2023 | americanbankingnews.com

Adagene Inc. (NASDAQ:ADAG) Short Interest Down 10.9% in February

March 14, 2023 | finance.yahoo.com

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

January 9, 2023 | finance.yahoo.com

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

January 5, 2023 | finance.yahoo.com

Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9

March 27, 2023 | Investor Place Media (Ad)

The "King Of Quants" sees 10X potential...

Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...

December 22, 2022 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC) and Adagene (ADAG)

December 19, 2022 | benzinga.com

After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO

December 16, 2022 | seekingalpha.com

Adagene adds 12% on clinical trial collaboration with Roche

December 16, 2022 | finance.yahoo.com

Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roche’s Standard-of-Care for First-Line Advanced Liver Cancer

November 21, 2022 | finance.yahoo.com

Adagene Appoints Cuong Do to Board of Directors and Audit Committee

November 14, 2022 | finance.yahoo.com

DelveInsight Highlights Major Advances, Transformative Therapies and 180+ Leading Players Wheeling the PD-1 and PD-L1 Inhibitors Pipeline Landscape

November 10, 2022 | finance.yahoo.com

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

October 11, 2022 | finance.yahoo.com

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November

September 10, 2022 | finance.yahoo.com

Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

September 1, 2022 | nz.finance.yahoo.com

Healee Lands $2M to Grow Customizable Telehealth Solution in the U.S.

August 30, 2022 | wsj.com

JW (Cayman) Therapeutics Co. Ltd.

August 30, 2022 | finance.yahoo.com

Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates

August 26, 2022 | benzinga.com

Global CD47 Inhibitor Drug Clinical Trial Report...

August 25, 2022 | finance.yahoo.com

Adagene Inc. (ADAG)

July 1, 2022 | seekingalpha.com

Micro-cap Adagene surges after hours on $10M share buyback

June 29, 2022 | marketwatch.com

Adagene ADSs Rise 16% After Co. Announces Repurchase Plan

June 29, 2022 | finance.yahoo.com

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million

June 26, 2022 | nasdaq.com

China’s Economy, Geopolitical Risk and Zero Covid Policies

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ADAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

ADAG Company Calendar

Today: 3/26/2023
Next Earnings (Estimated): 3/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ADAG
CUSIP: N/A
CIK: 1818838
Web: www.adagene.com
Phone: 86-512-8777-3632
Fax: N/A
Employees: 198
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +233.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.08
Current Ratio: 3.10
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $10.18 million
Price / Sales: 6.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.58 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 43,250,000
Free Float: 34,083,000
Market Cap: $64.88 million
Optionable: Not Optionable
Beta: 0.07

Key Executives

Dr. Peter P. Luo Ph.D. (Age 56)
Co-Founder, CEO & Chairman

Mr. Man Kin Tam M.B.A. (Age 45)
CFO & Director

Dr. Fangyong Du Ph.D. (Age 52)
Chief Technology Officer

Dr. Jc Xu M.D. (Age 57)
Ph.D., Chief Scientific Officer

Ms. Ami Celeste Knoefler
VP of Investor Relations & Corp. Communications

Ms. Ling Zhou
Head of HR

Dr. Qinghai Zhao (Age 61)
Chief Manufacturing Officer

Ms. Yan Li M.B.A. (Age 47)
Sr. VP of Bioinformatics & Information Technology

Ms. Xiaohong She (Age 55)
Sr. VP & Head of Clinical Operations

Dr. Guizhong Liu Ph.D. (Age 51)
Head of Biology & Pharmacology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ADAG Stock - Frequently Asked Questions

Should I buy or sell Adagene stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADAG shares.
View ADAG analyst ratings or view top-rated stocks.
What is Adagene's stock price forecast for 2023?: 2 equities research analysts have issued twelve-month price targets for Adagene's stock. Their ADAG share price forecasts range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for ADAG or view top-rated stocks among Wall Street analysts.
How have ADAG shares performed in 2023?: Adagene's stock was trading at $1.3250 at the start of the year. Since then, ADAG stock has increased by 13.2% and is now trading at $1.50.
View the best growth stocks for 2023 here.
When is Adagene's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our ADAG earnings forecast.
When did Adagene IPO?: (ADAG) raised $133 million in an initial public offering (IPO) on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager.
What is Adagene's stock symbol?: Adagene trades on the NASDAQ under the ticker symbol "ADAG."

Who are Adagene's major shareholders?: Adagene's stock is owned by a variety of retail and institutional investors. Top institutional investors include Strategic Vision Investment Ltd (0.84%) and Renaissance Technologies LLC (0.17%).
How do I buy shares of Adagene?: Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Adagene's stock price today?: One share of ADAG stock can currently be purchased for approximately $1.50.
How much money does Adagene make?: Adagene (NASDAQ:ADAG) has a market capitalization of $64.88 million and generates $10.18 million in revenue each year.
How many employees does Adagene have?: The company employs 198 workers across the globe.
How can I contact Adagene?: Adagene's mailing address is 4F BUILDING C14 NO. 218 XINGHU STREET SUZHOU INDUSTRIAL PARK, JIANGSU F4, 215123. The official website for the company is www.adagene.com. The company can be reached via phone at 86-512-8777-3632 or via email at ir@adagene.com.

This page (NASDAQ:ADAG) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adagene - ADAG Stock Forecast, Price & News

Adagene MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Adagene (NASDAQ:ADAG) Stock

ADAG Stock News Headlines

ADAG Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ADAG Stock - Frequently Asked Questions

Overall MarketRank^™